Our hypothesis is that patients with intrathecal delivery systems for chronic non-cancer pain will report no improvement treatment efficacy when compared to patients with chronic pain managed with oral or systemic opioid therapies. Our secondary hypothesis is that patients with intrathecal delivery systems for chronic non-cancer pain will report no improvement in treatment efficacy when compared to patients with chronic pain who are managed with non-opioid therapies.

Inclusion Criteria:

• Males or females greater than 18 years of age with legal decision making ability.
• Subjects receiving care at the Brigham and Women's Hospital Pain Management Center.
• Subjects must have a history of chronic pain > 6 months and must have been a patient in the BWH Pain Center > 6 months.

Exclusion Criteria:

• Pain due to metastatic cancer or to cancer that is locally invasive
• Patients with a primary diagnosis of spasticity, receiving intrathecal baclofen
• Evidence of psychosis or hospitalization for psychiatric illness during study
• Pregnancy at any time during the study
• Altered mental status that would make subject unable to complete outcome questionnaires
• Significant chronic medical illness, such that requires frequent hospitalization or health care utilization (ie: renal failure requiring dialysis, heart failure or cardiac disease requiring surgery or intensive care admission, pulmonary disease requiring intubation or hospitalization, pancreatitis requiring hospitalization, vascular disease requiring surgery or hospitalization, etc.)

Males or females greater than 18 years of age History of chronic pain greater than 6 months Patient in the BWH Pain Center for greater than 6 months